MNPR (Monopar Therapeutics) Float Percentage Of Total Shares Outstanding: 68.26% (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNPR Monopar Therapeutics Inc MNPR
34 GF Score
Price $108.10
! 3 Warning Signs
View Full Analysis

What is Monopar Therapeutics Float Percentage Of Total Shares Outstanding?

Monopar Therapeutics MNPR -1.61% 34 Float Percentage Of Total Shares Outstanding is 68.26% as of Jul. 27, 2026. GuruFocus rates MNPR with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Monopar Therapeutics's float shares is 4.57 Mil. Monopar Therapeutics's total shares outstanding is 6.70 Mil. Monopar Therapeutics's float percentage of total shares outstanding is 68.26%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Monopar Therapeutics's Insider Ownership is 7.30%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Monopar Therapeutics's Institutional Ownership is 97.54%.

MNPR
34GF Score
Monopar Therapeutics Inc MNPR
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Monopar Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=4.57/6.70
=68.26%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 68.26% mean?
Monopar Therapeutics (MNPR) has a Float Percentage Of Total Shares Outstanding of 68.26% as of Jul. 27, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Monopar Therapeutics and its competitors.
Is Monopar Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Monopar Therapeutics' current Float Percentage Of Total Shares Outstanding is 68.26%. Overall, Monopar Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Float Percentage Of Total Shares Outstanding compare to DSGN and CLYM?
Monopar Therapeutics' Float Percentage Of Total Shares Outstanding of 68.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current Float Percentage Of Total Shares Outstanding is 68.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Float Percentage Of Total Shares Outstanding of 68.26%. The current Float Percentage Of Total Shares Outstanding is 68.26%. Monopar Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Float Percentage Of Total Shares Outstanding is 68.26% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Other Exchanges 1IY0:Germany
Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
34GF Score

Get the complete analysis for MNPR

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$108.10
Price